Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics

Boehringer Ingelheim collaborates with Envisagenics to target cancer-specific RNA alterations in solid tumors using AI-centered technology.

Boehringer Ingelheim has entered a collaboration with Envisagenics to target cancer-specific RNA alterations in solid tumors using AI-centered technology.

The collaboration aims to leverage Envisagenics' platform to identify potential targets for precision treatments.

Boehringer Ingelheim will utilize various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates, and T cell engagers.